PositiveID CEO Details New Distribution Agreement with Leading Non-Invasive Patient Monitoring Technology Company

Agreement for new Bluetooth thermometer and other topics discussed in interview with CEOLIVE.TV

Delray Beach, Florida, UNITED STATES

DELRAY BEACH, Fla., June 20, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (the “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today a new interview with Chairman and CEO William J. Caragol that details the Company’s private label distribution agreement, announced June 18th, with a global leader in non-invasive patient monitoring systems.

The Interview may be viewed here.  

In the interview, Caragol describes the Company’s development of the latest version of the Caregiver® non-contact thermometer and its expected impact on the Company’s medical device business.

The Caregiver thermometer is the world’s first non-contact device with TouchFree™ technology developed by the inventors of tympanic thermometry.

Caragol also provides an update on the Company’s other initiatives year-to-date, including its FireflyDX, real-time PCR breadboard prototype pathogen detection system. 

The FireflyDX family of products is being developed in both portable and handheld forms to provide accurate, rapid pathogen detection using real-time polymerase chain reaction (PCR) in less than 30 minutes, with minimally trained personnel and at a lower cost than existing systems.

Current solutions for accurately identifying potential pathogens and bio-threats, especially at the point of care (POC), can sometimes take as long as several days to provide results, dramatically delaying what is often life-saving treatment or quarantine measures.

About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

Statements about PositiveID's future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to complete the development, testing and commercialization of the FireflyDX-Portable and FireflyDX-Handheld; the Company’s ability to target the professional healthcare market; the Company’s ability to raise capital; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 2, 2018, and 10-Qs filed on May 18, 2018, November 13, 2017, and August 14, 2017, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.


Contact Data